330 related articles for article (PubMed ID: 28704384)
41. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer.
Bernier MO; Morel O; Rodien P; Muratet JP; Giraud P; Rohmer V; Jeanguillaume C; Bigorgne JC; Jallet P
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1418-21. PubMed ID: 16133388
[TBL] [Abstract][Full Text] [Related]
43. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
[TBL] [Abstract][Full Text] [Related]
44. An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Bible KC; Menefee ME; Lin CJ; Millward MJ; Maples WJ; Goh BC; Karlin NJ; Kane MA; Adkins DR; Molina JR; Donehower RC; Lim WT; Flynn PJ; Richardson RL; Traynor AM; Rubin J; LoRusso PM; Smallridge RC; Burton JK; Suman VJ; Kumar A; Voss JS; Rumilla KM; Kipp BR; Chintakuntlawar AV; Harris P; Erlichman C
Thyroid; 2020 Sep; 30(9):1254-1262. PubMed ID: 32538690
[No Abstract] [Full Text] [Related]
45. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.
Wang C; Zhao T; Li H; Gao W; Lin Y
Nucl Med Commun; 2017 May; 38(5):366-371. PubMed ID: 28362717
[TBL] [Abstract][Full Text] [Related]
46. Measuring the extent of total thyroidectomy for differentiated thyroid carcinoma using radioactive iodine imaging: relationship with serum thyroglobulin and clinical outcomes.
Holsinger FC; Ramaswamy U; Cabanillas ME; Lang J; Lin HY; Busaidy NL; Grubbs E; Rahim S; Sturgis EM; Lee JE; Weber RS; Clayman GL; Rohren EM
JAMA Otolaryngol Head Neck Surg; 2014 May; 140(5):410-5. PubMed ID: 24700275
[TBL] [Abstract][Full Text] [Related]
47. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
48. Comparing the efficacy of thyroglobulin and thyroglobulin/ thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy.
Ju Y; Wang L; Cheng F; Huang F; Chen X; Song Q; Xiao J; Zhu X; Jia H
BMC Endocr Disord; 2023 Jan; 23(1):19. PubMed ID: 36670396
[TBL] [Abstract][Full Text] [Related]
49. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
50. Lung Metastasis in Children with Differentiated Thyroid Cancer: Factors Associated with Diagnosis and Outcomes of Therapy.
Chesover AD; Vali R; Hemmati SH; Wasserman JD
Thyroid; 2021 Jan; 31(1):50-60. PubMed ID: 32517539
[No Abstract] [Full Text] [Related]
51. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
52. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
53. Serum Thyroglobulin Measurement Following Surgery Without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review.
Chou R; Dana T; Brent GA; Goldner W; Haymart M; Leung AM; Ringel MD; Sosa JA
Thyroid; 2022 Jun; 32(6):613-639. PubMed ID: 35412871
[No Abstract] [Full Text] [Related]
54. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
55. Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant in patients with low-intermediate-risk differentiated thyroid cancer.
Zhang Q; Xu W
Nucl Med Commun; 2022 Oct; 43(10):1051-1057. PubMed ID: 35972341
[TBL] [Abstract][Full Text] [Related]
56. Role of Postoperative Stimulated Thyroglobulin as Prognostic Factor for Differentiated Thyroid Cancer in Children and Adolescents.
Zanella A; Scheffel RS; Pasa MW; Dora JM; Maia AL
Thyroid; 2017 Jun; 27(6):787-792. PubMed ID: 28292215
[TBL] [Abstract][Full Text] [Related]
57. Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine.
Zhang X; Higuchi T; Tomonaga H; Lamid-Ochir O; Bhattarai A; Nguyen-Thu H; Taketomi-Takahashi A; Hirasawa H; Tsushima Y
Nucl Med Commun; 2020 Apr; 41(4):350-355. PubMed ID: 32032192
[TBL] [Abstract][Full Text] [Related]
58. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
59. Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody.
Jia Q; Meng Z; Xu K; He X; Tan J; Zhang G; Li X; Liu N; Hu T; Zhou P; Wang S; Upadhyaya A; Liu X; Wang H; Zhang C
Sci Rep; 2017 Feb; 7():43516. PubMed ID: 28240744
[TBL] [Abstract][Full Text] [Related]
60. Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma.
Frank RW; Middleton L; Stack BC; Spencer HJ; Riggs AT; Bodenner DL
Head Neck; 2014 Feb; 36(2):155-7. PubMed ID: 23728951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
